Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600630635> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2600630635 endingPage "396.e1" @default.
- W2600630635 startingPage "386" @default.
- W2600630635 abstract "BackgroundThe present study examined real-world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first-line (1L) bevacizumab (BEV)- or cetuximab (CET)-containing regimen in 1L or 1L-through-second-line (1L-2L) therapy.Patients and MethodsUsing a large US insurance claims database, patients with mCRC initiating 1L BEV- or 1L CET-containing regimen from January 1, 2008 to September 30, 2014 were identified. The per-patient per-month (PPPM) all-cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic-containing regimen, 1L-2L therapy. Multivariable regression analyses were used to compare PPPM total health care costs between patients initiating a 1L BEV- versus 1L CET-containing regimen.ResultsA total of 6095 patients initiating a 1L BEV- and 453 initiating a 1L CET-containing regimen were evaluated for 1L costs; 2218 patients initiating a 1L BEV- and 134 initiating a 1L CET-containing regimen were evaluated for 1L-2L costs. In 1L therapy, 1L CET had adjusted PPPM costs that were $3135 (95% confidence interval [CI], $1174-$5040; P < .001) greater on average than 1L BEV. In 1L-2L therapy, 1L BEV-2L CET had adjusted PPPM costs that were $1402 (95% CI, $1365-$1442; P = .010) greater than those for 1L BEV-2L BEV, and 1L CET-2L BEV had adjusted PPPM costs that were $4279 (95% CI, $4167-$4400; P = .001) greater on average than those for 1L BEV-2L BEV. The adjusted PPPM cost differences for 1L BEV-2L other biologic or 1L CET-2L other biologic agent were numerically greater but statistically insignificant.ConclusionPPPM total health care costs for 1L and 2L therapy tended to be greater for patients treated with 1L CET-containing regimens than for 1L BEV-containing regimens. Also, continuing treatment with BEV-containing regimens 1L-2L was less costly than switching between BEV and CET. The cost differences between BEV and CET hold important implications for treatment decisions of mCRC patients in real-world clinical practice." @default.
- W2600630635 created "2017-04-07" @default.
- W2600630635 creator A5016806055 @default.
- W2600630635 creator A5026035409 @default.
- W2600630635 creator A5051420725 @default.
- W2600630635 creator A5051465568 @default.
- W2600630635 creator A5067577806 @default.
- W2600630635 creator A5067868620 @default.
- W2600630635 creator A5077652159 @default.
- W2600630635 creator A5085738876 @default.
- W2600630635 creator A5086837839 @default.
- W2600630635 date "2017-12-01" @default.
- W2600630635 modified "2023-10-18" @default.
- W2600630635 title "Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy" @default.
- W2600630635 cites W2070052294 @default.
- W2600630635 cites W2140951757 @default.
- W2600630635 cites W2159303174 @default.
- W2600630635 doi "https://doi.org/10.1016/j.clcc.2017.03.014" @default.
- W2600630635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28619608" @default.
- W2600630635 hasPublicationYear "2017" @default.
- W2600630635 type Work @default.
- W2600630635 sameAs 2600630635 @default.
- W2600630635 citedByCount "7" @default.
- W2600630635 countsByYear W26006306352018 @default.
- W2600630635 countsByYear W26006306352019 @default.
- W2600630635 countsByYear W26006306352020 @default.
- W2600630635 countsByYear W26006306352022 @default.
- W2600630635 countsByYear W26006306352023 @default.
- W2600630635 crossrefType "journal-article" @default.
- W2600630635 hasAuthorship W2600630635A5016806055 @default.
- W2600630635 hasAuthorship W2600630635A5026035409 @default.
- W2600630635 hasAuthorship W2600630635A5051420725 @default.
- W2600630635 hasAuthorship W2600630635A5051465568 @default.
- W2600630635 hasAuthorship W2600630635A5067577806 @default.
- W2600630635 hasAuthorship W2600630635A5067868620 @default.
- W2600630635 hasAuthorship W2600630635A5077652159 @default.
- W2600630635 hasAuthorship W2600630635A5085738876 @default.
- W2600630635 hasAuthorship W2600630635A5086837839 @default.
- W2600630635 hasBestOaLocation W26006306351 @default.
- W2600630635 hasConcept C121608353 @default.
- W2600630635 hasConcept C126322002 @default.
- W2600630635 hasConcept C143998085 @default.
- W2600630635 hasConcept C2776694085 @default.
- W2600630635 hasConcept C2777802072 @default.
- W2600630635 hasConcept C2778336483 @default.
- W2600630635 hasConcept C2779998722 @default.
- W2600630635 hasConcept C2781413609 @default.
- W2600630635 hasConcept C526805850 @default.
- W2600630635 hasConcept C71924100 @default.
- W2600630635 hasConceptScore W2600630635C121608353 @default.
- W2600630635 hasConceptScore W2600630635C126322002 @default.
- W2600630635 hasConceptScore W2600630635C143998085 @default.
- W2600630635 hasConceptScore W2600630635C2776694085 @default.
- W2600630635 hasConceptScore W2600630635C2777802072 @default.
- W2600630635 hasConceptScore W2600630635C2778336483 @default.
- W2600630635 hasConceptScore W2600630635C2779998722 @default.
- W2600630635 hasConceptScore W2600630635C2781413609 @default.
- W2600630635 hasConceptScore W2600630635C526805850 @default.
- W2600630635 hasConceptScore W2600630635C71924100 @default.
- W2600630635 hasIssue "4" @default.
- W2600630635 hasLocation W26006306351 @default.
- W2600630635 hasLocation W26006306352 @default.
- W2600630635 hasOpenAccess W2600630635 @default.
- W2600630635 hasPrimaryLocation W26006306351 @default.
- W2600630635 hasRelatedWork W1993235655 @default.
- W2600630635 hasRelatedWork W2051540233 @default.
- W2600630635 hasRelatedWork W2098707609 @default.
- W2600630635 hasRelatedWork W2563870823 @default.
- W2600630635 hasRelatedWork W2617055067 @default.
- W2600630635 hasRelatedWork W2712978371 @default.
- W2600630635 hasRelatedWork W2997878878 @default.
- W2600630635 hasRelatedWork W349909140 @default.
- W2600630635 hasRelatedWork W4294845050 @default.
- W2600630635 hasRelatedWork W88596221 @default.
- W2600630635 hasVolume "16" @default.
- W2600630635 isParatext "false" @default.
- W2600630635 isRetracted "false" @default.
- W2600630635 magId "2600630635" @default.
- W2600630635 workType "article" @default.